Most patients with metastatic melanoma still develop primary or acquired resistance to immune checkpoint inhibition (ICI). Here the authors report the results of a phase II trial of cryoablation and ICI in patients with unresectable melanoma progressing on ICI.
- Meghan J. Mooradian
- Florian J. Fintelmann
- Ryan J. Sullivan
